^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ac-225 ErbB3 targeted radiotherapy

    i
    Other names: Ac-225 ErbB3 targeted radiotherapy, Actinium-225 ErbB3 targeting radiotherapy, Ac-225-HER3-ARC, 225Ac-HER3-ARC, Actinium-225 (Ac-225)-conjugated anti-HER3 antibody
    Company:
    Actinium, LG Chem
    Drug class:
    HER3 inhibitor, α radiation emission
    Related drugs:
    1year
    Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors (AACR 2023)
    In this study, both 225Ac-HER3 ARC and 177Lu-HER3 ARC demonstrated significant antitumor activity against HER3-expressing tumors in a dose-dependent manner. The HER3 targeted radiotherapy approach that we have undertaken could potentially overcome the limitations of current solid tumor therapies in resistance settings and warrants further evaluation in patients with HER3-expressing tumors.
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    ERBB3 expression
    |
    Ac-225 ErbB3 targeted radiotherapy • 177Lu-HER3 ARC